D. Vassilief

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

Christian Rosé, Sabine Bréchignac, D. Vassilief et al. · Leukemia Research · 2010 · 195 citations

Chelation Therapy, Medicine, Iron Metabolism +6

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

Christian Rosé, Sabine Bréchignac, D. Vassilief et al. · Blood · 2007 · 73 citations

A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies

Didier Bouscary, Laurence Legros, M Tulliez et al. · British Journal of Haematology · 2005 · 48 citations · Full text

Hematological Malignancy, Thrombosis, Groupe Français +15

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Raphaël Itzykson, Sameh Ayari, D. Vassilief et al. · Leukemia · 2009 · 30 citations

Hematological Malignancy, Bone Marrow Failure, Mixed-phenotype Acute Leukemia +10

Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment.

Charles M. Ginsburg, Dominique Salmon‐Céron, D. Vassilief et al. · PubMed · 1997 · 24 citations

Ritonavir Treatment, Unusual Occurrence, Hematology +2